Beam Therapeutics Inc. Operating Lease, Weighted Average Discount Rate, Percent
Beam Therapeutics Inc. (BEAM) had Operating Lease, Weighted Average Discount Rate, Percent of 7.30% as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-02-24
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 7.30%.
- 2024-12-31: Operating Lease, Weighted Average Discount Rate, Percent 7.30%.
- 2023-12-31: Operating Lease, Weighted Average Discount Rate, Percent 7.60%.
- 2022-12-31: Operating Lease, Weighted Average Discount Rate, Percent 7.50%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2025-12-31 | 7.30% 10-K · filed 2026-02-24 |
| 2024-12-31 | 7.30% 10-K · filed 2026-02-24 |
| 2023-12-31 | 7.60% 10-K · filed 2025-02-25 |
| 2022-12-31 | 7.50% 10-K · filed 2024-02-27 |
| 2022-09-30 | 7.50% 10-Q · filed 2022-11-07 |
| 2022-06-30 | 7.40% 10-Q · filed 2022-08-09 |
| 2022-03-31 | 7.00% 10-Q · filed 2022-05-09 |
| 2021-12-31 | 7.00% 10-K · filed 2023-02-28 |
| 2021-09-30 | 7.10% 10-Q · filed 2021-11-08 |
| 2021-06-30 | 7.10% 10-Q · filed 2021-08-10 |
| 2021-03-31 | 7.10% 10-Q · filed 2021-05-11 |
| 2020-12-31 | 7.40% 10-K · filed 2022-02-28 |
| 2020-09-30 | 9.70% 10-Q · filed 2020-11-10 |
| 2020-06-30 | 9.70% 10-Q · filed 2020-08-12 |
| 2020-03-31 | 9.70% 10-Q · filed 2020-05-12 |
| 2019-12-31 | 9.80% 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |